Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026.
Daix (France), New York City (New York, United States), June 9,2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined General Meeting of June 30, 2026.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.